抗菌剤 N-n-butyl-1,2-benzisothiazolin-3-one の安全性試験
2. 催奇形性試験
2001 年 45 巻 3 号 p. 143-148
詳細
2001 年 45 巻 3 号 p. 143-148
Groups of 20 pregnant Wistar rats were treated orally with an antimicrobial agent, N-n-butyl-1, 2-benzisothiazolin-3-one (BBIT), from day 7 through 17 of gestation at doses of 0, 40, 120 or 360mg/kg. Maternal toxicity in the 360mg/kg group was evident from decreased body weight gain and food consumption. Increase in stomach weights and decrease in thymus weights were observed at doses more than 120mg/kg. No treatment-related fetal anomalies were noted in any dose groups. Reduced degree of fetal ossification at 360mg/kg was attributed to reduced fetal weight at that dose level. These findings indicate that BBIT has no teratogenic effects in rats. The maternal and developmental NOAELs are considered as 40mg/kg and 120mg/kg, respectively.
